Pharmaceuticals, Biotechnology and Life Sciences
–Rocket’s Largest Lentiviral Pipeline Opportunity with an Estimated Prevalence of 3,000 to 8,000 Patients in the U.S. and EU– –Phase…
– Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients – -Tivozanib-Nivolumab Combination Generally Well…
The U.S. Food and Drug Administration approved on Friday Novo Nordisk’s Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise.
Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million…
Clinically meaningful improvement of 25 ETDRS letters equivalent versus nadir of BCVA in GS010-treated eyes at 96 weeks Results coherent…
Ipsen’s study of Dysport treatment of patients with personalized diary-based rehabilitation program improved patients’ voluntary movement as measured by a composite active range of motion (CXA) outcome.
Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization.
The U.S. Food and Drug Administration issued a draft guidance Friday outlining the goals and implementation of a new voluntary conformity assessment initiative, the Accreditation Scheme for Conformity Assessment (ASCA) Pilot, designed to promote consistency and predictability in the premarket review process for medical devices, encourage effective use of FDA resources, and enhance regulatory efficiency, while also enhancing confidence in medical device testing.
The National Institutes of Health awarded six research grants for studies to develop a learning health care system for the treatment of early psychosis, as part of a broad research initiative called Early Psychosis Intervention Network (EPINET), which aims to develop models for the effective delivery of coordinated specialty care (CSC) services for early psychosis.
The global digital dose inhalers market size will grow by $989.44 million during 2019-2023, according to a Technavio report.